ALS Untangled says evidence is insufficient to support regular ISRIB use in ALS
Original source
ISRIB (opens in a new tab)ALS Untangled reports that ISRIB has shown benefits in cell models of familial ALS, while some people with ALS in Spain report subjective symptom improvements. Objective evidence is lacking, and no published clinical trials of ISRIB exist. The review says there is not enough information to support its regular use for treating ALS.
Why this matters
This means ISRIB should not be considered an established ALS treatment. People with ALS and clinicians still need evidence about its safety, tolerability, pharmacokinetics and effectiveness before its role can be assessed.
Limitations and context
This is an independent expert review, not a published clinical trial. The reported human experience comes from subjective reports by a group of people with ALS, without objective evidence. The review also notes unresolved concerns about ISRIB’s solubility and bioavailability in humans, and says further studies are needed.